Drug costs

The real-world strategies used to manage the high cost of specialty meds.

The Trump Administration has taken a large interest in PBM drug rebates, which they say create higher drug prices. But do they?

Louisiana’s subscription model aims to rein in the hepatitis C epidemic in the state.

Here’s how experts predict healthcare will unfold in 2019.

The biosimilar market is flourishing in Europe-why aren’t we seeing similar gains in the U.S.?

The value and benefits of biosimilars are increasingly becoming more apparent. Here are four areas where they are growing the most.

Cancer medication spending is unsustainable, but significant savings can be achieved just by reducing waste. Here’s how.

How can payers cope with new, ultra-expensive therapies?

While promising new options keep entering the scene, high costs can be problematic to patients and healthcare organizations. Here are some ways to cope.

Drug costs are increasing, but so is patient cost sharing. That’s raising serious problems for some patients. Here are seven of the most out-of-reach drugs due to high costs, according to industry watchers.

Reference pricing models are emerging as increasingly popular approaches for lowering drug costs.

Have two minutes? Listen to this quick podcast for critical takeaways from three of our top articles.

Healthcare experts weigh in on the president’s plan to lower drug prices. Here’s what they said.

PBMs are in a unique position to leverage three critical tools to protect patients from unnecessary healthcare costs.

Two new studies reveal that cost-restraints can keep patients from accessing life-preserving cancer drugs.

A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.

Autologous stem cell therapy may offer hope for patients with COPD. But some say caution is necessary.

CVS Health’s Troyen A. Brennan, MD, MPH, brings attention to a unique specialty pharmacy model and value-based contracting.

Here are four ways CMS’ final rule related to the 340B Drug Pricing Program could affect the healthcare industry.

PBMs make the argument for DIR fees after a litany of complaints from industry stakeholders.

A new UC Berkeley study has surprising findings about reference pricing and patient drug selection.

An eye-opening study by Precision for Value assesses cancer value frameworks.

An Avalere study has interesting findings about payer acceptance of biosimilars.